Cipla: Difference between revisions

What links here Related changes Page information Get shortened URL
Created by Yamaguchi先生
Last edited February 18, 2026
← Older edit
VisualWikitext
m Removed empty portal template using script
improved formatting based on references for accuracy
 
Line 1: Line 1:
{{Short description|Indian multinational pharmaceutical company}}
{{Short description|Indian multinational pharmaceutical company}}
{{multiple issues|
{{advert|date=June 2017}}
{{tone|date=June 2017}}
}}
{{EngvarB|date=January 2016}}
{{Use dmy dates|date=January 2016}}
{{Use dmy dates|date=January 2016}}
{{other uses|CIPLA (disambiguation)}}
{{Infobox company
{{Infobox company
| name = Cipla Limited
| name = Cipla Limited
| logo = Cipla logo.svg
| logo = Cipla logo.svg
| logo_size = 250px
| logo_size = 250px
| trading_name = Cipla
| former_name = Chemical Industrial & Pharmaceutical Laboratories Ltd. (1935–1984)
| type = [[Public company|Public]]
| type = [[Public company|Public]]
| traded_as = {{BSE|500087}}<br />{{NSE|CIPLA}}<br />[[NIFTY 50|NSE NIFTY 50 Constituent]]
| traded_as = {{BSE|500087}}<br />{{NSE|CIPLA}}<br />[[NIFTY 50|NSE NIFTY 50]] constituent
| founder = [[Khwaja Abdul Hamied]]
| founder = [[Khwaja Abdul Hamied]]
| area_served = Worldwide
| area_served = Worldwide
| key_people = [[Yusuf Hamied|Y. K. Hamied]]<br />{{small|([[Chairman]])}}<br />Umang Vohra<br />{{small|([[CEO]])}}
| key_people = {{Unbulleted_list|[[Yusuf Hamied|Y. K. Hamied]] {{small|([[Chairperson]])}}|Umang Vohra {{small|([[Chief executive officer|CEO]])}}}}
| ISIN = INE059A01026
| ISIN = {{ISIN|sl=n|pl=y|INE059A01026}}
| industry = [[Pharmaceuticals]]
| industry = [[Pharmaceuticals]]
| products = [[Pharmaceutical]]s and [[Medical diagnosis|diagnostics]]
| products = {{hlist|[[Medication|Pharmaceutical drugs]]| [[generic drug]]s| [[antiviral drug]]s| [[over-the-counter drug]]s| [[vaccine]]s| [[Medical diagnosis|diagnostics]]| [[contact lens]]es| [[Veterinary medicine|animal health]]| [[dietary supplements]]|[[protein supplement]]s }}
| revenue = {{Increase}} {{INRConvert|17476.19|c}}<ref name=pnl>{{Cite web|title=Cipla Consolidated Profit & Loss account, Cipla Financial Statement & Accounts|url=https://www.moneycontrol.com/financials/cipla/consolidated-profit-lossVI/C|access-date=2020-07-28|website=www.moneycontrol.com|language=en}}</ref>
| revenue = {{Increase}} {{INRConvert|27548|c}} (2025)
| revenue_year = 2020
| operating_income = {{Increase}} {{INRConvert|7128|c}} (2025)
| operating_income = {{Increase}} {{INRConvert|3205.99|c}}<ref>{{Cite web|title=Cipla Consolidated Profit & Loss account, Cipla Financial Statement & Accounts|url=https://www.moneycontrol.com/financials/cipla/consolidated-profit-loss/C|access-date=2020-06-21|website=www.moneycontrol.com|language=en}}</ref>
| net_income = {{Increase}} {{INRConvert|5273|c}} (2025)
| income_year = 2020
| assets = {{Increase}} {{INRConvert|37387|c}} (2025)
| net_income = {{Increase}} {{INRConvert|1546.98|c}}<ref name=pnl/>
| equity = {{Increase}} {{INRConvert|31289|c}} (2025)
| net_income_year = 2020
| num_employees = 27,764 (March 2024)<ref>{{cite web |title=Annual Report 2023-24 |url=https://www.cipla.com/sites/default/files/Annual-Report-2023-24-%28Double%20page%29.pdf |access-date=24 May 2025 |archive-date=5 October 2024 |archive-url=https://web.archive.org/web/20241005175111/https://www.cipla.com/sites/default/files/Annual-Report-2023-24-%28Double%20page%29.pdf |url-status=live }}</ref>
| assets = {{Decrease}} {{INRConvert|23662.56|c}}<ref name=bs>{{Cite web|title=Cipla Consolidated Balance Sheet, Cipla Financial Statement & Accounts|url=https://www.moneycontrol.com/financials/cipla/consolidated-balance-sheetVI/C|access-date=2020-07-28|website=www.moneycontrol.com|language=en}}</ref>
| assets_year = 2020
| equity = {{Increase}} {{INRConvert|15763.00|c}}<ref name=bs/>
| equity_year = 2020
| num_employees = 22,036<ref name=BRR201314>{{cite web |url=http://www.cipla.com/CiplaSite/Media/PDF/Business_Responsibility_Report_2013_14.pdf |title=Business Responsibility Report 2013-14 |publisher=Cipla |date=15 July 2014 |access-date=17 September 2014 |archive-url=https://web.archive.org/web/20150317170629/http://www.cipla.com/CiplaSite/Media/PDF/Business_Responsibility_Report_2013_14.pdf |archive-date=17 March 2015 |url-status=dead }}</ref>
| parent =  
| parent =  
| subsid = Invagen Pharmaceuticals
| subsid = Invagen Pharmaceuticals
| homepage = [http://www.cipla.com www.cipla.com]
| homepage = [http://www.cipla.com www.cipla.com]
| footnotes =
| foundation = {{Start date and age|1935||p=y}}
| foundation = {{Start date and age|1935|p=y}}
| location = [[Mumbai]], [[Maharashtra]], India
| location = [[Mumbai, Maharashtra]], India
| footnotes = Financials {{as of|2025|03|31|lc=y|df=yes}}.<ref>{{cite web |title=Q4 & FY25 results |url=https://www.cipla.com/sites/default/files/Cipla_Q4FY25%20Press%20Release_3.pdf |publisher=Cipla |access-date=24 May 2025 |archive-date=14 May 2025 |archive-url=https://web.archive.org/web/20250514161520/https://www.cipla.com/sites/default/files/Cipla_Q4FY25%20Press%20Release_3.pdf |url-status=live }}</ref><ref>{{cite web |title=Audited Financial Results (Standalone and Consolidated) for year ended 31st March 2025 |url=https://www.cipla.com/sites/default/files/signed-Financial-Results-13052025-signed.pdf |publisher=Cipla |access-date=24 May 2025}}</ref>
}}
}}
'''Cipla Limited''' is an Indian multinational [[pharmaceutical]] company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat [[respiratory disease]], [[cardiovascular disease]], [[arthritis]], [[diabetes]], [[Depression (mood)|depression]] and many other medical conditions.<ref>{{Cite web|url=http://www.thehindubusinessline.com/companies/how-a-little-blue-pill-changed-ciplas-fortunes/article5670851.ece|title=How a little blue pill changed Cipla's fortunes}}</ref>
'''Cipla Limited''' is an Indian [[Multinational corporation|multinational]] [[pharmaceutical]] company headquartered in [[Mumbai]]. Cipla primarily focuses on developing medication to treat [[respiratory disease]], [[cardiovascular disease]], [[arthritis]], [[diabetes]], [[Depression (mood)|depression]], [[Pediatrics|paediatric]] and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in [[India]].<ref>{{cite news |title=Cipla betting big on digitisation and emerging segments |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-betting-big-on-digitisation-and-emerging-segments/articleshow/93406373.cms |access-date=6 December 2022 |work=The Economic Times}}</ref><ref>{{cite news |title=Cipla betting big on digitisation and emerging segments |url=https://www.financialexpress.com/healthcare/cipla-betting-big-on-digitisation-and-emerging-segments/2620470/ |access-date=6 December 2022 |work=Financial Express |language=en}}</ref>
 
As of 17 September 2014, its [[market capitalisation]] was {{INRConvert|49611.58|c|lk=|year=2018}}, making it India's 42nd largest publicly traded company by [[market value]].<ref>{{cite web |url=http://www.moneycontrol.com/stocks/marketinfo/marketcap/nse/index.html |title=Top Companies by Market Capitalisation |publisher=Money Control |date=17 September 2014 |access-date=17 September 2014}}</ref><ref>[http://www.thehindubusinessline.com/companies/cipla-to-sell-msds-hiv-drug-in-india/article5709467.ece Cipla to sell MSD’s HIV drug in India | Business Line<!-- Bot generated title -->]</ref><ref>[http://www.thehindubusinessline.com/companies/cipla-hetero-to-roll-out-biosimilar-drug/article6129559.ece Cipla, Hetero to roll out biosimilar drug | Business Line<!-- Bot generated title -->]</ref>
 
On 23 April 2019, Cipla appointed Dr. Raju Mistry as Global Chief People Officer.<ref>{{Cite news|url=https://business.medicaldialogues.in/cipla-appoints-dr-raju-mistry-as-global-chief-people-officer/|title=Cipla appoints Dr Raju Mistry as Global Chief People Officer|date=2019-04-23|newspaper=Medical Dialogues|language=en-IN|access-date=2019-04-23}}</ref>


==History ==
==History ==
In 1935, Cipla was founded by [[Khwaja Abdul Hamied]] as 'The '''C'''hemical, '''I'''ndustrial & '''P'''harmaceutical '''La'''boratories' in Mumbai.<ref name=History>{{cite web |url=http://www.cipla.com/Home/About-Us/History.aspx |title=About us - History |publisher=Cipla Limited |access-date=3 November 2014 |archive-url=https://web.archive.org/web/20151027060707/http://www.cipla.com/Home/About-Us/History.aspx |archive-date=27 October 2015 |url-status=dead }}</ref><ref name=ETHistory>{{cite web |url=http://economictimes.indiatimes.com/cipla-ltd/infocompanyhistory/companyid-13917.cms |title=Company History - Cipla Ltd. |publisher=Economic Times |access-date=3 November 2013}}</ref>
After meeting [[Mahatma Gandhi]] in the early 1920s, [[Khwaja Abdul Hamied]] decided to contribute to the [[Swadeshi movement]] by pursuing a doctorate in chemistry. In 1935, Hamied founded Cipla as the Chemical, Industrial & Pharmaceutical Laboratories in [[Mumbai]].<ref name=History>{{cite web |url=http://www.cipla.com/Home/About-Us/History.aspx |title=About us - History |publisher=Cipla Limited |access-date=3 November 2014 |archive-url=https://web.archive.org/web/20151027060707/http://www.cipla.com/Home/About-Us/History.aspx |archive-date=27 October 2015 |url-status=dead }}</ref><ref name=ETHistory>{{cite web |url=http://economictimes.indiatimes.com/cipla-ltd/infocompanyhistory/companyid-13917.cms |title=Company History - Cipla Ltd. |publisher=Economic Times |access-date=3 November 2013 |archive-date=15 November 2013 |archive-url=https://web.archive.org/web/20131115195132/http://economictimes.indiatimes.com/cipla-ltd/infocompanyhistory/companyid-13917.cms |url-status=live }}</ref> During [[World War II]], the company became the largest supplier of [[quinine]] and [[Vitamin B12]] for [[Allies of World War II|Allied soldiers]].<ref name=":2">{{Cite book |last=Eban |first=Katherine |title=Bottle of Lies |date=2019 |publisher=[[HarperCollins]] |isbn=9780062338785 |pages=69-73}}</ref> The company name shortened to its current form in July 1984.<ref name=ETHistory/> Upon Hamied's death in 1972, his son [[Yusuf Hamied]], a Cambridge-educated chemist, took over the company.<ref name=":2" />
In July 1984, the name of the company was changed to 'Cipla Limited'.<ref name=ETHistory/>


In 1985, the US FDA approved the company's bulk drug against HIV and other drugs to treat poor people in the developing world.<ref name="Interview with Yusuf Hamied">{{cite web |url=http://www.hbs.edu/businesshistory/emerging-markets/pages/profile-detail.aspx?profile=yhamied |title=Interview with Yusuf Hamied |website=Creating Emerging Markets |publisher=Harvard Business School}}</ref>
In 1995, Cipla launched [[Deferiprone]], the world's first oral iron chelator.<ref name="History" /> In 1999, Cipla joined the [[Indian Pharmaceutical Alliance]] as a founding member in an effort to promote the development of generic drugs in India.<ref name=":0">{{Cite news |last=Dec 22 |first=PTI |date=2022-12-22 |title=Indian pharma sector set for 'volume to value leadership' journey in 2023 |work=The Economic Times |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharma-sector-set-for-volume-to-value-leadership-journey-in-2023/articleshow/96407749.cms |access-date=2023-08-05 |issn=0013-0389 |archive-date=5 August 2023 |archive-url=https://web.archive.org/web/20230805170626/https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharma-sector-set-for-volume-to-value-leadership-journey-in-2023/articleshow/96407749.cms |url-status=live }}</ref><ref>{{Cite web |title=Introducing IPA- Indian Pharmaceutical Alliance |url=https://www.ipa-india.org/about-ipa/introduction/ |access-date=2023-08-05 |website=IPA, Indian Pharmaceutical Alliance |archive-date=9 April 2024 |archive-url=https://web.archive.org/web/20240409041116/https://www.ipa-india.org/about-ipa/introduction/ |url-status=live }}</ref> During the [[HIV/AIDS|AIDS]] epidemic in the early 2000s, Hamied reverse-engineered a three-drug [[antiretroviral]] medication that was sold for about $12,000 per year to create a cheaper version that sold for $304 per year.<ref name=":1">{{Cite news |date=2023-08-05 |title=Epic saga of Cipla: How a swadeshi Robin Hood took on Big Pharma of the West |work=The Economic Times |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/epic-saga-of-cipla-how-a-swadeshi-robin-hood-took-on-big-pharma-of-the-west/articleshow/102440967.cms?from=mdr |access-date=2023-08-05 |issn=0013-0389}}</ref> This drug was sold to African charities and governments. It is estimated that "at one time, as much as 40 percent of the AIDS patients in poor countries took Cipla drugs".<ref name=":1" />
Led by the founder's son Yusuf Hamied, a Cambridge-educated chemist, the company provided generic AIDS and other drugs to treat poor people in the developing world.<ref name="Interview with Yusuf Hamied"/>
In 1995, Cipla launched [[Deferiprone]], the world's first oral iron chelator.<ref name=History/> In 2001, Cipla offered [[antiretroviral]]s for HIV treatment at a fractional cost (less than $350 per year per patient).<ref>{{cite news |url=http://usatoday30.usatoday.com/news/world/2001-02-07-aidscocktail.htm |title=Indian drug company offers cheap AIDS drugs |newspaper=USA Today |date=19 June 2001 |access-date=3 November 2013}}</ref>


In 2013 Cipla acquired the South African company Cipla-Medpro, kept it as a subsidiary, and changed its name to Cipla Medpro South Africa Limited.<ref name=VC>{{cite news|last1=Jawani|first1=Lohit|title=Cipla completes acquisition of South Africa's Cipla Medpro|url=http://www.vccircle.com/news/pharmaceuticals/2013/07/16/cipla-completes-acquisition-south-africa%E2%80%99s-cipla-medpro|work=VC Circle|date=16 July 2013|access-date=8 September 2016|archive-url=https://web.archive.org/web/20160315164809/http://www.vccircle.com/news/pharmaceuticals/2013/07/16/cipla-completes-acquisition-south-africa%E2%80%99s-cipla-medpro|archive-date=15 March 2016|url-status=dead}}</ref><ref name=Delists>{{cite web|title=Delists from JSE|url=http://www.bdlive.co.za/business/healthcare/2013/07/16/cipla-medpro-delists-from-jse-as-cipla-deal-is-finalised|publisher=Business Day Live|access-date=13 July 2013|date=2013}}</ref>  At the time of the acquisition Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third biggest pharmaceutical company.<ref name=VC/>   The company had been founded in 2002 and was known as Enaleni Pharmaceuticals Ltd.<ref>{{cite web|title=Enaleni Pharmaceuticals Limited Prospectus 2005|url=http://globaldocuments.morningstar.com/documentlibrary/document/e00037afcc0c3668.msdoc/original|publisher=Morningstar|access-date=8 September 2016}}</ref> In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company,<ref>{{cite web|last1=Avafia|first1=Tenu|last2=Berger|first2=Jonathan|last3=Hartzenberg|first3=Trudi|title=The ability of select sub-Saharan African countries to utilise TRIPs Flexibilities and Competition Law to ensure a sustainable supply of essential medicines: A study of producing and importing countries|publisher=WHO|url=http://apps.who.int/medicinedocs/documents/s18249en/s18249en.pdf|archive-url=https://web.archive.org/web/20140123042922/http://apps.who.int/medicinedocs/documents/s18249en/s18249en.pdf|url-status=dead|archive-date=23 January 2014|date=2006}}</ref> and in 2008 it changed its name to Cipla-Medpro.<ref>{{cite web|last1=Kahn|first1=Tamar|title=South Africa: Enaleni Takes Name of Its Unit Cipla-Medpro|url=http://allafrica.com/stories/200809100609.html|publisher=All Africa|date=10 September 2008}}</ref>
During the [[avian flu pandemic]] in 2006, Cipla was able to reverse-engineer the drug Tamiflu and sell it for significantly lower prices.<ref name=":0" /> In 2013, Cipla acquired the [[South Africa]]n company Cipla-Medpro. Its name was changed to Cipla Medpro South Africa Limited and was kept as a subsidiary.<ref name="VC">{{cite news|last1=Jawani|first1=Lohit|title=Cipla completes acquisition of South Africa's Cipla Medpro|url=http://www.vccircle.com/news/pharmaceuticals/2013/07/16/cipla-completes-acquisition-south-africa%E2%80%99s-cipla-medpro|work=VC Circle|date=16 July 2013|access-date=8 September 2016|archive-url=https://web.archive.org/web/20160315164809/http://www.vccircle.com/news/pharmaceuticals/2013/07/16/cipla-completes-acquisition-south-africa%E2%80%99s-cipla-medpro|archive-date=15 March 2016|url-status=dead}}</ref><ref name="Delists">{{cite web|title=Delists from JSE|url=http://www.bdlive.co.za/business/healthcare/2013/07/16/cipla-medpro-delists-from-jse-as-cipla-deal-is-finalised|publisher=Business Day Live|access-date=13 July 2013|date=2013|archive-date=1 August 2013|archive-url=https://web.archive.org/web/20130801130715/http://www.bdlive.co.za/business/healthcare/2013/07/16/cipla-medpro-delists-from-jse-as-cipla-deal-is-finalised|url-status=live}}</ref>  At the time of the acquisition, Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third-biggest pharmaceutical company.<ref name="VC" /> The company had been founded in 2002 under the name Enaleni Pharmaceuticals Ltd.<ref>{{cite web|title=Enaleni Pharmaceuticals Limited Prospectus 2005|url=http://globaldocuments.morningstar.com/documentlibrary/document/e00037afcc0c3668.msdoc/original|publisher=Morningstar|access-date=8 September 2016|archive-date=19 September 2016|archive-url=https://web.archive.org/web/20160919174446/http://globaldocuments.morningstar.com/documentlibrary/document/e00037afcc0c3668.msdoc/original|url-status=live}}</ref> In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company;<ref>{{cite web|last1=Avafia|first1=Tenu|last2=Berger|first2=Jonathan|last3=Hartzenberg|first3=Trudi|title=The ability of select sub-Saharan African countries to utilise TRIPs Flexibilities and Competition Law to ensure a sustainable supply of essential medicines: A study of producing and importing countries|publisher=WHO|url=http://apps.who.int/medicinedocs/documents/s18249en/s18249en.pdf|archive-url=https://web.archive.org/web/20140123042922/http://apps.who.int/medicinedocs/documents/s18249en/s18249en.pdf|url-status=dead|archive-date=23 January 2014|date=2006}}</ref> in 2008, it changed its name to Cipla-Medpro.<ref>{{cite web|last1=Kahn|first1=Tamar|title=South Africa: Enaleni Takes Name of Its Unit Cipla-Medpro|url=http://allafrica.com/stories/200809100609.html|publisher=All Africa|date=10 September 2008}}</ref> In September 2023, it was announced Cipla South Africa had acquired the [[Midrand]]-headquartered healthcare products manufacturer, Actor Pharma.<ref>{{Cite web |last=Priyan |first=Vishnu |date=2023-09-05 |title=Cipla to bolster OTC portfolio with acquisition of Actor Pharma |url=https://www.pharmaceutical-technology.com/news/cipla-acquisition-actor-pharma/ |access-date=2023-09-05 |website=Pharmaceutical Technology |language=en-US |archive-date=5 September 2023 |archive-url=https://web.archive.org/web/20230905140500/https://www.pharmaceutical-technology.com/news/cipla-acquisition-actor-pharma/ |url-status=live }}</ref>


In 2019 Cipla entered [[digital therapeutics]] by partnering with Wellthy Therapeutics in India and Brandmed in South Africa.<ref>{{Cite web |date=n.d. |title=Cipla's History |url=https://www.cipla.com/about-us/our-history |access-date=2022-05-16 |website=Cipla South Africa |language=en-US}}</ref>
In September 2015, Cipla acquired InvaGen Pharmaceuticals and Exelan Pharmaceuticals, two American pharmaceutical companies, for 555 million dollars.<ref>{{Cite journal |last=JARVIS |first=LISA |title=Mylan Will Buy Most of Matrix |date=2006-09-04 |url=http://dx.doi.org/10.1021/cen-v084n036.p008 |journal=Chemical & Engineering News Archive |volume=84 |issue=36 |pages=8 |doi=10.1021/cen-v084n036.p008 |issn=0009-2347 |url-access=subscription}}</ref> In 2019, Cipla entered [[digital therapeutics]] by partnering with Wellthy Therapeutics in [[India]] and Brandmed in [[South Africa]].<ref>{{Cite web |date=n.d. |title=Cipla's History |url=https://www.cipla.com/about-us/our-history |access-date=2022-05-16 |website=Cipla South Africa |language=en-US |archive-date=26 May 2022 |archive-url=https://web.archive.org/web/20220526182900/https://www.cipla.com/about-us/our-history |url-status=live }}</ref> In April 2024, Cipla acquired Ivia Beaute Pvt Ltd's cosmetics and personal care distribution and marketing business for ₹130 crore.<ref>{{Cite news|url=https://www.business-standard.com/companies/news/cipla-to-acquire-ivia-beaute-s-cosmetics-personal-care-biz-for-rs-130-cr-124041600197_1.html|title=Cipla to acquire Ivia Beaute's cosmetics, personal care biz for Rs 130 cr|newspaper=Business Standard India|date=16 April 2024|agency=Press Trust of India|archive-date=21 April 2024|access-date=21 April 2024|archive-url=https://web.archive.org/web/20240421070218/https://www.business-standard.com/companies/news/cipla-to-acquire-ivia-beaute-s-cosmetics-personal-care-biz-for-rs-130-cr-124041600197_1.html|url-status=live}}</ref>


==Products and services==
==Products and services==
Cipla sells [[active pharmaceutical ingredients]] to other manufacturers as well as pharmaceutical and personal care products,<ref name=BW>{{cite web |url=http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=CIPLA:IN |archive-url=https://archive.today/20131106234625/http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=CIPLA:IN |url-status=dead |archive-date=6 November 2013 |title=cipla ltd (CIPLA:Natl India) |publisher=Business Week |access-date=7 November 2013 }}</ref> including [[escitalopram oxalate]] (anti-depressant), [[lamivudine]], and [[fluticasone propionate]].<ref name=BRR201314>{{cite web |url=http://www.cipla.com/CiplaSite/Media/PDF/Business_Responsibility_Report_2013_14.pdf |title=Business Responsibility Report 2013-14 |publisher=Cipla |date=15 July 2014 |access-date=17 September 2014 |archive-url=https://web.archive.org/web/20150317170629/http://www.cipla.com/CiplaSite/Media/PDF/Business_Responsibility_Report_2013_14.pdf |archive-date=17 March 2015 |url-status=dead }}</ref> They are the world's largest manufacturer of [[antiretroviral drugs]].<ref name=BW/><ref>{{cite press release |url=http://www.prnewswire.com/news-releases/aids-healthcare-foundation-campaign-challenges-cipla-over-drug-pricing-in-india-profit-at-what-cost-aids-drugs-for-all-57993227.html |title=AIDS Healthcare Foundation Campaign Challenges Cipla Over Drug Pricing in India |publisher=PR Newswire |date=8 August 2007 |access-date=4 November 2013}}</ref>
Cipla sells [[active pharmaceutical ingredients]] to other manufacturers as well as pharmaceutical and personal care products,<ref name=BW>{{cite web |url=http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=CIPLA:IN |archive-url=https://archive.today/20131106234625/http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=CIPLA:IN |url-status=dead |archive-date=6 November 2013 |title=cipla ltd (CIPLA:Natl India) |publisher=Business Week |access-date=7 November 2013 }}</ref> including the anti-depressant [[escitalopram oxalate]], [[lamivudine]], and [[fluticasone propionate]].<ref>{{cite web |url=https://www.cipla.com/sites/default/files/Annual-Report-FY-2022-23.pdf |title=Annual Report FY 2022-23 |publisher=Cipla |date=15 July 2014 |access-date=October 11, 2023 |archive-url=https://web.archive.org/web/20231011194716/https://www.cipla.com/sites/default/files/Annual-Report-FY-2022-23.pdf |archive-date=2023-10-11 |url-status=live |website=Cipla.com}}</ref> Cipla is the world's largest manufacturer of [[antiretroviral drugs]].<ref name=BW/><ref>{{cite press release |url=http://www.prnewswire.com/news-releases/aids-healthcare-foundation-campaign-challenges-cipla-over-drug-pricing-in-india-profit-at-what-cost-aids-drugs-for-all-57993227.html |title=AIDS Healthcare Foundation Campaign Challenges Cipla Over Drug Pricing in India |publisher=PR Newswire |date=8 August 2007 |access-date=4 November 2013 |archive-date=29 August 2014 |archive-url=https://web.archive.org/web/20140829220651/http://www.prnewswire.com/news-releases/aids-healthcare-foundation-campaign-challenges-cipla-over-drug-pricing-in-india-profit-at-what-cost-aids-drugs-for-all-57993227.html |url-status=live }}</ref>


In July 2020, the company announced the introduction of [[Gilead Sciences]]' ''[[Remdesivir]]'' under the brand name '''CIPREMI''' in India after reaching a voluntary licensing agreement with parent companyand [[DCGI]] approval for "restricted emergency use" in [[COVID-19]] treatment of critical confirmed patients.<ref>{{cite news |date=21 June 2020 |title=India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug |language=en |work=Reuters |url=https://www.reuters.com/article/us-health-coronavirus-india-remdesivir/india-gives-hetero-labs-and-cipla-approval-to-make-gileads-covid-19-drug-idUSKBN23S0EO}}</ref><ref>{{cite news |title=Coronavirus drug: Cipla launches Cipremi's, claims it is the cheapest Remdesivir |url=https://www.financialexpress.com/lifestyle/health/cipla-launches-remdesivir-claims-it-is-inexpensive/2018015/ |work=The Financial Express |date=9 July 2020}}</ref><ref>{{cite news |title=Coronavirus drug: Cipla ramps up production of antiviral remdesivir amid demand spurt |url=https://www.businesstoday.in/current/corporate/coronavirus-drug-cipla-ramps-up-production-of-covid-19-antiviral-remdesivir/story/409758.html |work=businesstoday.in}}</ref>
In July 2020, the company announced the introduction of [[Gilead Sciences]]' [[Remdesivir]] under the brand name CIPREMI in India after reaching a voluntary licensing agreement with the parent company and [[DCGI]] approval for "restricted emergency use" in [[COVID-19]] treatment of patients in critical condition.<ref>{{cite news |date=21 June 2020 |title=India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug |language=en |work=Reuters |url=https://www.reuters.com/article/us-health-coronavirus-india-remdesivir/india-gives-hetero-labs-and-cipla-approval-to-make-gileads-covid-19-drug-idUSKBN23S0EO |archive-date=5 August 2020 |access-date=7 August 2020 |archive-url=https://web.archive.org/web/20200805090151/https://www.reuters.com/article/us-health-coronavirus-india-remdesivir/india-gives-hetero-labs-and-cipla-approval-to-make-gileads-covid-19-drug-idUSKBN23S0EO |url-status=live }}</ref><ref>{{cite news |title=Coronavirus drug: Cipla launches Cipremi's, claims it is the cheapest Remdesivir |url=https://www.financialexpress.com/lifestyle/health/cipla-launches-remdesivir-claims-it-is-inexpensive/2018015/ |work=The Financial Express |date=9 July 2020 |archive-date=15 August 2020 |access-date=7 August 2020 |archive-url=https://web.archive.org/web/20200815173602/https://www.financialexpress.com/lifestyle/health/cipla-launches-remdesivir-claims-it-is-inexpensive/2018015/ |url-status=live }}</ref><ref>{{cite news |title=Coronavirus drug: Cipla ramps up production of antiviral remdesivir amid demand spurt |url=https://www.businesstoday.in/current/corporate/coronavirus-drug-cipla-ramps-up-production-of-covid-19-antiviral-remdesivir/story/409758.html |work=businesstoday.in}}</ref>


==Operations==
==Operations==


Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries.<ref>{{cite web|url=http://www.cipla.com/en/corporate-information/at-a-glance.html|title=Corporate Information: At a Glance|publisher=Cipla|access-date=6 July 2019|archive-url=https://web.archive.org/web/20160912104850/http://www.cipla.com/en/corporate-information/at-a-glance.html|archive-date=12 September 2016|url-status=dead}}</ref><ref>{{cite news |url=http://www.business-standard.com/article/news-cm/cipla-in-the-pink-of-health-113092500515_1.html |title=Cipla in the pink of health |newspaper=Business Standard |date=25 September 2013 |access-date=5 November 2013}}</ref> Exports accounted for 48% {{INRConvert|4948|c|lk=|year=2013}} of its revenue for FY 2013–14.<ref name=AR201314>{{cite web |url=http://www.cipla.com/CiplaSite/Media/PDF/2014_08_06_78th_Annual_Report_2013_14_001.pdf |title=Annual Report 2013-14 |publisher=Cipla |date=22 August 2014 |access-date=17 September 2014 |archive-url=https://web.archive.org/web/20150122062022/http://www.cipla.com/CiplaSite/Media/PDF/2014_08_06_78th_Annual_Report_2013_14_001.pdf |archive-date=22 January 2015 |url-status=dead }}</ref> Cipla spent {{INR}}517 crore (5.4% of their revenue) in FY 2013–14 on R&D activities.<ref name=AR201314/> The primary focus areas for R&D were development of new formulations, drug-delivery systems and APIs (active pharmaceutical ingredients). Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.
Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries.<ref>{{cite web|url=http://www.cipla.com/en/corporate-information/at-a-glance.html|title=Corporate Information: At a Glance|publisher=Cipla|access-date=6 July 2019|archive-url=https://web.archive.org/web/20160912104850/http://www.cipla.com/en/corporate-information/at-a-glance.html|archive-date=12 September 2016|url-status=dead}}</ref><ref>{{cite news |url=http://www.business-standard.com/article/news-cm/cipla-in-the-pink-of-health-113092500515_1.html |title=Cipla in the pink of health |newspaper=Business Standard |date=25 September 2013 |access-date=5 November 2013 |archive-date=2 October 2014 |archive-url=https://web.archive.org/web/20141002195051/http://www.business-standard.com/article/news-cm/cipla-in-the-pink-of-health-113092500515_1.html |url-status=live }}</ref> Exports accounted for 48% {{INRConvert|4948|c|lk=|year=2013}} of its revenue for the 2013–14 fiscal year.<ref name=AR201314>{{cite web |url=http://www.cipla.com/CiplaSite/Media/PDF/2014_08_06_78th_Annual_Report_2013_14_001.pdf |title=Annual Report 2013-14 |publisher=Cipla |date=22 August 2014 |access-date=17 September 2014 |archive-url=https://web.archive.org/web/20150122062022/http://www.cipla.com/CiplaSite/Media/PDF/2014_08_06_78th_Annual_Report_2013_14_001.pdf |archive-date=22 January 2015 |url-status=dead }}</ref> Cipla spent {{INR}}517 crore (5.4% of their revenue) in the 2013–14 fiscal year on R&D activities.<ref name=AR201314/> The primary focus areas for R&D were development of new formulations, drug-delivery systems, and APIs. Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.{{cn|date=July 2025}}


As on 31 March 2013, the company had 22,036 employees (out of which 2,455 were women (7.30%) and 23 were employees with disabilities (0.1%)).<ref name=BRR201314/> During the FY 2013–14, the company incurred {{INRConvert|1285|c|lk=|year=2014}} on employee benefit expenses.<ref name=AR201314/>
== Listings and shareholding==


== Listings and Shareholding==
The equity shares of Cipla are listed on the [[Bombay Stock Exchange]],<ref>{{cite web |url=http://www.bseindia.com/stock-share-price/cipla-ltd/cipla/500087/ |title=Cipla Limited |website=BSEindia.com |access-date=2 November 2013 |archive-date=4 November 2013 |archive-url=https://web.archive.org/web/20131104221916/http://www.bseindia.com/stock-share-price/cipla-ltd/cipla/500087/ |url-status=live }}</ref> where it is a constituent of the [[BSE SENSEX]] index,<ref>{{cite web |url=http://www.bseindia.com/indices/IndicesWatch_Weight.aspx?iname=BSE30&index_Code=16 |title=Scripwise Weightages in S&P BSE SENSEX |publisher=BSE India |access-date=2 November 2013 |archive-url=https://web.archive.org/web/20151201094728/http://www.bseindia.com/indices/IndicesWatch_Weight.aspx?iname=BSE30&index_Code=16 |archive-date=1 December 2015 |url-status=dead }}</ref> and the [[National Stock Exchange of India]],<ref>{{cite web |url=http://www.nseindia.com/live_market/dynaContent/live_watch/get_quote/GetQuote.jsp?symbol=CIPLA |title=NTPC Limited |publisher=NSE India |access-date=2 November 2013 |archive-date=4 March 2016 |archive-url=https://web.archive.org/web/20160304040205/http://www.nseindia.com/live_market/dynaContent/live_watch/get_quote/GetQuote.jsp?symbol=CIPLA |url-status=live }}</ref> where it is a constituent of the [[CNX Nifty]].<ref>{{cite web |url=http://www.nseindia.com/content/indices/ind_niftylist.csv |title=Download List of CNX Nifty stocks (.csv) |publisher=NSE India |access-date=2 November 2013 |archive-date=13 October 2013 |archive-url=https://web.archive.org/web/20131013143407/http://www.nseindia.com/content/indices/ind_niftylist.csv |url-status=live }}</ref> Its [[Global depository receipt|Global Depository Receipts]] (GDRs) are listed on the [[Luxembourg Stock Exchange]].<ref name=AR201314/>


The equity shares of Cipla are listed on the [[Bombay Stock Exchange]],<ref>{{cite web |url=http://www.bseindia.com/stock-share-price/cipla-ltd/cipla/500087/ |title=Cipla Limited |website=BSEindia.com |access-date=2 November 2013}}</ref> where it is a constituent of the [[BSE SENSEX]] index,<ref>{{cite web |url=http://www.bseindia.com/indices/IndicesWatch_Weight.aspx?iname=BSE30&index_Code=16 |title=Scripwise Weightages in S&P BSE SENSEX |publisher=BSE India |access-date=2 November 2013 |archive-url=https://web.archive.org/web/20151201094728/http://www.bseindia.com/indices/IndicesWatch_Weight.aspx?iname=BSE30&index_Code=16 |archive-date=1 December 2015 |url-status=dead }}</ref> and the [[National Stock Exchange of India]],<ref>{{cite web |url=http://www.nseindia.com/live_market/dynaContent/live_watch/get_quote/GetQuote.jsp?symbol=CIPLA |title=NTPC Limited |publisher=NSE India |access-date=2 November 2013}}</ref> where it is a constituent of the [[CNX Nifty]].<ref>{{cite web |url=http://www.nseindia.com/content/indices/ind_niftylist.csv |title=Download List of CNX Nifty stocks (.csv) |publisher=NSE India |access-date=2 November 2013}}</ref> Its [[Global depository receipt|Global Depository Receipts]] (GDRs) are listed on the [[Luxembourg Stock Exchange]].<ref name=AR201314/>
As of December 31, 2022, the promoter group, Y. K. Hamied and his family, held around 33.61% equity shares in Cipla. Individual shareholders hold approximately 14.72% of its shares. [[SBI Mutual Fund]], [[Life Insurance Corporation of India|LIC]] etc. are the largest non-promoter shareholders in the Company.<ref>{{Cite web |title=StockEdge |url=https://web.stockedge.com/share/cipla/5128?section=shareholders |access-date=2023-01-25 |website=web.stockedge.com |archive-date=25 January 2023 |archive-url=https://web.archive.org/web/20230125133547/https://web.stockedge.com/share/cipla/5128?section=shareholders |url-status=live }}</ref> In January 2024, Samina Hamied resigned from her position as the Executive Vice Chairperson of Cipla. She continued to serve the company as a non-executive director subject to rotational retirement.{{cn|date=July 2025}}
As of 30 September 2014, the promoter group, Y. K. Hamied and his family, held around 36.80% equity shares in Cipla. Around 148,000 individual shareholders held approx. 18.67% of its shares.<ref name=Shareholding>{{cite web |url=http://www.cipla.com/CiplaSite/Media/Images/Banner/Shareholding-pattern-as-on-30th-September-2013.pdf |title=Shareholding pattern as on 30th September, 2013 |publisher=Cipla Limited |access-date=2 November 2013 |archive-url=https://web.archive.org/web/20131102201429/http://www.cipla.com/CiplaSite/Media/Images/Banner/Shareholding-pattern-as-on-30th-September-2013.pdf |archive-date=2 November 2013 |url-status=dead }}</ref> [[Life Insurance Corporation of India|LIC]] is the largest non-promoter shareholder with approx. 6.45% shareholding in the company by the end of September 2013.<ref>{{cite web |url=http://www.moneycontrol.com/bse/shareholding/shp_public_shares.php?sc_dispid=C#C |title=CIPLA - Shareholding belonging to the category : "Public and holding more than 1% of the Total No.of Shares" |website=MoneyControl.com |date=30 September 2013 |access-date=4 November 2013}}</ref>
{| class="wikitable"
{| class="wikitable"
|-
|-
! Shareholders (as on 31-March-2014) !! Shareholding<ref name=Shareholding/>
! Shareholders (as on 31-December-2022) !! Shareholding<ref>{{Cite web |title=Latest CIPLA Shareholding Pattern |url=https://www.equitymaster.com/stock-research/shareholding-pattern/CIPL/CIPLA-Shareholding-Pattern |access-date=2023-01-25 |website=Equitymaster |archive-date=25 January 2023 |archive-url=https://web.archive.org/web/20230125133551/https://www.equitymaster.com/stock-research/shareholding-pattern/CIPL/CIPLA-Shareholding-Pattern |url-status=live }}</ref>
|-
|-
| Promoter Group|| 36.80%
| Promoter Group|| 33.61%
|-
|-
| Foreign Institutional Investors (FII)|| 23.32%
| Mutual funds|| 14.09%
|-
|-
| Individual shareholders|| 19.00%
|Financial Institution/Banks/Insurance
|4.96%
|-
|-
| Insurance companies|| 10.30%
| Foreign Institutional Investors (FII)|| 28.39%
|-
|-
| Private Corporate Bodies|| 04.68%
|Corporate Bodies
|0.53%
|-
|-
| Mutual Funds and Unit Trust of India|| 04.43%
| Individuals|| 14.72%
|-
|-
| Non Resident Indians, Foreign Corporate Bodies and Others|| 03.46%
|NRIs/OCBs
|0.88%
|-
|-
| Global Depository Receipts|| 01.10%
|ADRs/GDRs
|NIL
|-
| Others|| 2.82%
|-
|-


| '''Total'''||'''100.00 %'''
| '''Total'''||'''100.00%'''
|}
|}


==Awards and recognitions==
==Awards and recognitions==
* In 2012, Cipla received the Thomson Reuters India Innovation Award.<ref>[http://pharmabiz.com/NewsDetails.aspx?aid=72283&sid=1 DBT, Cipla get Thomson Reuters India innovation awards<!-- Bot generated title -->]</ref>
* In 1980, Cipla won Chemexcil Award for Excellence for exports.<ref name="IIHistory">{{cite web |title=Company Profile - Cipla Limited |url=http://www.indiainfoline.com/Markets/Company/Background/Company-Profile/Cipla-Ltd/500087 |access-date=3 November 2013 |website=IndiaInfoline.com |archive-date=5 November 2013 |archive-url=https://web.archive.org/web/20131105133022/http://www.indiainfoline.com/Markets/Company/Background/Company-Profile/Cipla-Ltd/500087 |url-status=live }}</ref>
* Cipla won Dun & Bradstreet American Express Corporate Awards in 2006.<ref>{{cite web |url=http://www.dnb.co.in/top500/photogal5.html |archive-url=https://archive.today/20131104104713/http://www.dnb.co.in/top500/photogal5.html |url-status=dead |archive-date=4 November 2013 |title=Pharmaceutical sector award |publisher=Dun & Bradstreet |date=10 September 2006 |access-date=3 November 2013 }}</ref>
* In 2006, Cipla won Dun & Bradstreet American Express Corporate Awards.<ref>{{cite web |date=10 September 2006 |title=Pharmaceutical sector award |url=http://www.dnb.co.in/top500/photogal5.html |url-status=dead |archive-url=https://archive.today/20131104104713/http://www.dnb.co.in/top500/photogal5.html |archive-date=4 November 2013 |access-date=3 November 2013 |publisher=Dun & Bradstreet}}</ref>
* In 2007, [[Forbes Asia|Forbes]] included Cipla in the 200 'Best under a billion' list of best small Asian companies.<ref>{{cite news |url=http://articles.economictimes.indiatimes.com/2005-11-17/news/27509362_1_forbes-list-asia-pacific-list-asian-paints |title=Asian Paints, Cipla in Forbes list |newspaper=Economic Times |date=17 November 2005 |access-date=3 November 2013}}</ref>
* In 2007, [[Forbes Asia|Forbes]] included Cipla in the 200 'Best under a billion' list of best small Asian companies.<ref>{{cite news |date=17 November 2005 |title=Asian Paints, Cipla in Forbes list |newspaper=Economic Times |url=http://articles.economictimes.indiatimes.com/2005-11-17/news/27509362_1_forbes-list-asia-pacific-list-asian-paints |archive-url=https://web.archive.org/web/20131104193134/http://articles.economictimes.indiatimes.com/2005-11-17/news/27509362_1_forbes-list-asia-pacific-list-asian-paints |url-status=dead |archive-date=4 November 2013 |access-date=3 November 2013}}</ref>
* In 1980, Cipla won Chemexcil Award for Excellence for exports.<ref name=IIHistory>{{cite web |url=http://www.indiainfoline.com/Markets/Company/Background/Company-Profile/Cipla-Ltd/500087 |title=Company Profile - Cipla Limited |website=IndiaInfoline.com |access-date=3 November 2013}}</ref>
* In 2012, Cipla received the Thomson Reuters India Innovation Award.<ref>{{Cite web |url=http://pharmabiz.com/NewsDetails.aspx?aid=72283&sid=1 |title=DBT, Cipla get Thomson Reuters India innovation awards<!-- Bot generated title --> |access-date=24 November 2012 |archive-date=22 July 2013 |archive-url=https://web.archive.org/web/20130722095704/http://pharmabiz.com/NewsDetails.aspx?aid=72283&sid=1 |url-status=dead }}</ref>
* In 2015, Cipla stood third in the [[India's Most Reputed Brands]] (Pharmaceutical) list,<ref>"[https://economictimes.indiatimes.com/lupinsun-pharma-and-cipla-amongst-tops-most-reputed-pharma-brand-list/articleshow/53742154.cms Lupin, Sun Pharma and Cipla amongst tops most reputed pharma brand list]". ''The Economic Times''. timesofindia.com. 17 August 2016. Retrieved 6 July 2019.</ref> in a study conducted by BlueBytes,<ref>http://www.bluebytes.info</ref> a leading Media Analytics firm in association with TRA Research,<ref>http://www.trustadvisory.info</ref> a brand insights organization (both a part of the Comniscient Group).
* In 2015, Cipla stood third in the India's Most Reputed Brands (Pharmaceutical) list,<ref>"[https://economictimes.indiatimes.com/lupinsun-pharma-and-cipla-amongst-tops-most-reputed-pharma-brand-list/articleshow/53742154.cms Lupin, Sun Pharma and Cipla amongst tops most reputed pharma brand list]". ''The Economic Times''. timesofindia.com. 17 August 2016. Retrieved 6 July 2019.</ref> in a study conducted by BlueBytes,<ref>{{cite web |url=http://www.bluebytes.info/ |title=Home |website=bluebytes.info |access-date=7 August 2022 |archive-date=1 August 2018 |archive-url=https://web.archive.org/web/20180801073109/http://www.bluebytes.info/ |url-status=live }}</ref> a Media Analytics firm in association with TRA Research,<ref>{{cite web |url=http://www.trustadvisory.info/ |title=Home |website=trustadvisory.info |access-date=7 August 2022 |archive-date=2 November 2017 |archive-url=https://web.archive.org/web/20171102143617/http://www.trustadvisory.info/ |url-status=live }}</ref> a brand insights organization (both part of the Comniscient Group).


==Criticism==
==Criticism==


===Emergency contraception===
===Emergency contraception===
In August 2007, Cipla launched an [[emergency contraception]] drug "i-pill" sold [[over the counter]],<ref>{{cite news |url=http://www.hindustantimes.com/business-news/cipla-rises-on-morning-after-pill/article1-251319.aspx |archive-url=https://web.archive.org/web/20150205102533/http://www.hindustantimes.com/business-news/cipla-rises-on-morning-after-pill/article1-251319.aspx |url-status=dead |archive-date=5 February 2015 |title=Cipla rises on morning-after pill |newspaper=Hindustan Times |date=5 October 2007 |access-date=3 November 2013}}</ref> which was controversial with regard to its being available without a prescription and the large amount of drug contained per dose.<ref>{{cite news |url=http://healthcare.financialexpress.com/200710/market09.shtml |title=Cipla Launches i-pill |newspaper=Financial Express |access-date=3 November 2013}}</ref><ref>{{cite news |url=http://www.financialexpress.com/news/-ipill-by-cipla-draws-criticism-from-experts/232556 |title='i-pill' by Cipla draws criticism from experts |newspaper=Financial Express |date=27 October 2007 |access-date=3 November 2013}}</ref>
In August 2007, Cipla launched an [[emergency contraception]] drug "i-pill" sold [[over the counter]],.<ref>{{cite news |url=http://www.hindustantimes.com/business-news/cipla-rises-on-morning-after-pill/article1-251319.aspx |archive-url=https://web.archive.org/web/20150205102533/http://www.hindustantimes.com/business-news/cipla-rises-on-morning-after-pill/article1-251319.aspx |url-status=dead |archive-date=5 February 2015 |title=Cipla rises on morning-after pill |newspaper=Hindustan Times |date=5 October 2007 |access-date=3 November 2013}}</ref> The drug sparked controversy as it was available without prescription and contained a large amount of API per dosage.<ref>{{cite news |url=http://healthcare.financialexpress.com/200710/market09.shtml |title=Cipla Launches i-pill |newspaper=Financial Express |access-date=3 November 2013 |archive-date=4 November 2013 |archive-url=https://web.archive.org/web/20131104084353/http://healthcare.financialexpress.com/200710/market09.shtml |url-status=live }}</ref><ref>{{cite news |url=http://www.financialexpress.com/news/-ipill-by-cipla-draws-criticism-from-experts/232556 |title='i-pill' by Cipla draws criticism from experts |newspaper=Financial Express |date=27 October 2007 |access-date=3 November 2013 |archive-date=4 November 2013 |archive-url=https://web.archive.org/web/20131104081841/http://www.financialexpress.com/news/-ipill-by-cipla-draws-criticism-from-experts/232556 |url-status=live }}</ref>


===Generic drugs===
===Generic drugs===
In the late 1960s, Cipla began manufacturing a new, patented drug, [[propranolol]], without the permission of the drug's patent holder, [[Imperial Chemical Industries]] (ICI), which protested to the Indian government. The CEO of Cipla pressured the [[First Indira Gandhi ministry|government of Indira Gandhi]] to change India's [[patent laws]] to eliminate patents that directly covered drugs, and instead to allow only patents that covered [[Chemical synthesis|methods to make drugs]].<ref name=Wired>{{cite news |url=https://www.wired.com/wired/archive/14.12/indiadrug.html |title=The Treasure of Mumbai |newspaper=Wired Magazine |date=December 2006 |access-date=4 November 2013}}</ref> so that Cipla could go ahead and produce as many low-priced generic drugs for the poor as possible. Since then Cipla has also produced a low-cost drug to treat HIV, and expanded operations into several developing countries, including African nations, where most HIV and poor patients existed at one time.<ref name=nationalherald>{{cite news |url=https://www.nationalheraldindia.com/india/heart-warming-story-of-the-hamieds-who-set-up-cipla-and-have-been-saving-lives |title= Heart-warming story of the Hamieds, who set up CIPLA and have been saving lives |newspaper=National Herald |date=April 2020 |access-date=12 April 2020}}</ref> But the changes made led to criticism of both India's patent laws and Cipla.<ref>{{cite web|url=http://biohealthinvestor.com/2007/01/indian-generic-drug-maker-targets-sad-americans.html |title=Indian Generic Drug Maker Targets Sad Americans |website=biohealthinvestor.com |date=3 January 2007 |access-date=4 November 2013}}</ref> India reinstated patents on drugs in 2005.<ref name=Wired/>
In the late 1960s, Cipla began manufacturing a new, patented drug, [[propranolol]], without the permission of the drug's patent holder, [[Imperial Chemical Industries]]; a protest was filed with the Indian government. The CEO of Cipla pressured the [[First Indira Gandhi ministry|government of Indira Gandhi]] to change India's [[patent laws]] to eliminate patents that directly covered drugs, and instead to allow only patents that covered [[chemical synthesis|methods to make drugs]]<ref name=Wired>{{cite news |url=https://www.wired.com/wired/archive/14.12/indiadrug.html |title=The Treasure of Mumbai |newspaper=Wired Magazine |date=December 2006 |access-date=4 November 2013}}</ref> so that Cipla could produce low-priced generic drugs. Since then, Cipla has also produced a low-cost drug to treat HIV, and expanded operations into several developing countries.<ref name=nationalherald>{{cite news |url=https://www.nationalheraldindia.com/india/heart-warming-story-of-the-hamieds-who-set-up-cipla-and-have-been-saving-lives |title= Heart-warming story of the Hamieds, who set up CIPLA and have been saving lives |newspaper=National Herald |date=April 2020 |access-date=12 April 2020}}</ref> The changes made led to criticism of both India's patent laws and Cipla.<ref>{{cite web |url=http://biohealthinvestor.com/2007/01/indian-generic-drug-maker-targets-sad-americans.html |title=Indian Generic Drug Maker Targets Sad Americans |website=biohealthinvestor.com |date=3 January 2007 |access-date=4 November 2013 |archive-date=22 August 2012 |archive-url=https://web.archive.org/web/20120822022509/http://biohealthinvestor.com/2007/01/indian-generic-drug-maker-targets-sad-americans.html |url-status=live }}</ref> India reinstated patents on drugs in 2005.<ref name=Wired/>


==See also==
==See also==
Line 121: Line 111:
==External links==
==External links==
* {{Official website|http://www.cipla.com}}
* {{Official website|http://www.cipla.com}}
 
{{Portal bar|Companies|India}}
{{Nifty 200 companies}}
{{Nifty 200 companies}}
{{CNX Nifty companies}}
{{CNX Nifty companies}}
Line 130: Line 120:
[[Category:Pharmaceutical companies established in 1935]]
[[Category:Pharmaceutical companies established in 1935]]
[[Category:NIFTY 50]]
[[Category:NIFTY 50]]
[[Category:Biopharmaceutical companies]]
[[Category:Pharmaceutical companies]]
[[Category:Indian brands]]
[[Category:Indian brands]]
[[Category:Indian companies established in 1935]]
[[Category:Indian companies established in 1935]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]
[[Category:Companies listed on the Bombay Stock Exchange]]
[[Category:Multinational companies headquartered in India]]

Latest revision as of 14:32, 18 February 2026


For other uses, see CIPLA (disambiguation).
Cipla Limited
Cipla
Formerly
Chemical Industrial & Pharmaceutical Laboratories Ltd. (1935–1984)
Traded asBSE: 500087
NSE: CIPLA
NSE NIFTY 50 constituent
ISINTemplate:ISIN
IndustryPharmaceuticals
Founded1935 (91 years ago) (1935)
Founder(s)Khwaja Abdul Hamied
HeadquartersMumbai, Maharashtra, India
Area served
Worldwide
Key people
Products
RevenueIncrease ₹27,548 crore (US$3.9 billion) (2025)
Increase ₹7,128 crore (US$1.0 billion) (2025)
Increase ₹5,273 crore (US$740 million) (2025)
Total assetsIncrease ₹37,387 crore (US$5.2 billion) (2025)
Total equityIncrease ₹31,289 crore (US$4.4 billion) (2025)
Number of employees
27,764 (March 2024)[1]
SubsidiariesInvagen Pharmaceuticals
Websitewww.cipla.com
Footnotes / references
Financials as of 31 March 2025.[2][3]

Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India.[4][5]

History[edit | edit source]

After meeting Mahatma Gandhi in the early 1920s, Khwaja Abdul Hamied decided to contribute to the Swadeshi movement by pursuing a doctorate in chemistry. In 1935, Hamied founded Cipla as the Chemical, Industrial & Pharmaceutical Laboratories in Mumbai.[6][7] During World War II, the company became the largest supplier of quinine and Vitamin B12 for Allied soldiers.[8] The company name shortened to its current form in July 1984.[7] Upon Hamied's death in 1972, his son Yusuf Hamied, a Cambridge-educated chemist, took over the company.[8]

In 1995, Cipla launched Deferiprone, the world's first oral iron chelator.[6] In 1999, Cipla joined the Indian Pharmaceutical Alliance as a founding member in an effort to promote the development of generic drugs in India.[9][10] During the AIDS epidemic in the early 2000s, Hamied reverse-engineered a three-drug antiretroviral medication that was sold for about $12,000 per year to create a cheaper version that sold for $304 per year.[11] This drug was sold to African charities and governments. It is estimated that "at one time, as much as 40 percent of the AIDS patients in poor countries took Cipla drugs".[11]

During the avian flu pandemic in 2006, Cipla was able to reverse-engineer the drug Tamiflu and sell it for significantly lower prices.[9] In 2013, Cipla acquired the South African company Cipla-Medpro. Its name was changed to Cipla Medpro South Africa Limited and was kept as a subsidiary.[12][13] At the time of the acquisition, Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third-biggest pharmaceutical company.[12] The company had been founded in 2002 under the name Enaleni Pharmaceuticals Ltd.[14] In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company;[15] in 2008, it changed its name to Cipla-Medpro.[16] In September 2023, it was announced Cipla South Africa had acquired the Midrand-headquartered healthcare products manufacturer, Actor Pharma.[17]

In September 2015, Cipla acquired InvaGen Pharmaceuticals and Exelan Pharmaceuticals, two American pharmaceutical companies, for 555 million dollars.[18] In 2019, Cipla entered digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa.[19] In April 2024, Cipla acquired Ivia Beaute Pvt Ltd's cosmetics and personal care distribution and marketing business for ₹130 crore.[20]

Products and services[edit | edit source]

Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products,[21] including the anti-depressant escitalopram oxalate, lamivudine, and fluticasone propionate.[22] Cipla is the world's largest manufacturer of antiretroviral drugs.[21][23]

In July 2020, the company announced the introduction of Gilead Sciences' Remdesivir under the brand name CIPREMI in India after reaching a voluntary licensing agreement with the parent company and DCGI approval for "restricted emergency use" in COVID-19 treatment of patients in critical condition.[24][25][26]

Operations[edit | edit source]

Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries.[27][28] Exports accounted for 48% ₹4,948 crore (equivalent to ₹68 billion or US$950 million in 2019) of its revenue for the 2013–14 fiscal year.[29] Cipla spent ₹517 crore (5.4% of their revenue) in the 2013–14 fiscal year on R&D activities.[29] The primary focus areas for R&D were development of new formulations, drug-delivery systems, and APIs. Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.[citation needed]

Listings and shareholding[edit | edit source]

The equity shares of Cipla are listed on the Bombay Stock Exchange,[30] where it is a constituent of the BSE SENSEX index,[31] and the National Stock Exchange of India,[32] where it is a constituent of the CNX Nifty.[33] Its Global Depository Receipts (GDRs) are listed on the Luxembourg Stock Exchange.[29]

As of December 31, 2022, the promoter group, Y. K. Hamied and his family, held around 33.61% equity shares in Cipla. Individual shareholders hold approximately 14.72% of its shares. SBI Mutual Fund, LIC etc. are the largest non-promoter shareholders in the Company.[34] In January 2024, Samina Hamied resigned from her position as the Executive Vice Chairperson of Cipla. She continued to serve the company as a non-executive director subject to rotational retirement.[citation needed]

Shareholders (as on 31-December-2022) Shareholding[35]
Promoter Group 33.61%
Mutual funds 14.09%
Financial Institution/Banks/Insurance 4.96%
Foreign Institutional Investors (FII) 28.39%
Corporate Bodies 0.53%
Individuals 14.72%
NRIs/OCBs 0.88%
ADRs/GDRs NIL
Others 2.82%
Total 100.00%

Awards and recognitions[edit | edit source]

  • In 1980, Cipla won Chemexcil Award for Excellence for exports.[36]
  • In 2006, Cipla won Dun & Bradstreet American Express Corporate Awards.[37]
  • In 2007, Forbes included Cipla in the 200 'Best under a billion' list of best small Asian companies.[38]
  • In 2012, Cipla received the Thomson Reuters India Innovation Award.[39]
  • In 2015, Cipla stood third in the India's Most Reputed Brands (Pharmaceutical) list,[40] in a study conducted by BlueBytes,[41] a Media Analytics firm in association with TRA Research,[42] a brand insights organization (both part of the Comniscient Group).

Criticism[edit | edit source]

Emergency contraception[edit | edit source]

In August 2007, Cipla launched an emergency contraception drug "i-pill" sold over the counter,.[43] The drug sparked controversy as it was available without prescription and contained a large amount of API per dosage.[44][45]

Generic drugs[edit | edit source]

In the late 1960s, Cipla began manufacturing a new, patented drug, propranolol, without the permission of the drug's patent holder, Imperial Chemical Industries; a protest was filed with the Indian government. The CEO of Cipla pressured the government of Indira Gandhi to change India's patent laws to eliminate patents that directly covered drugs, and instead to allow only patents that covered methods to make drugs[46] so that Cipla could produce low-priced generic drugs. Since then, Cipla has also produced a low-cost drug to treat HIV, and expanded operations into several developing countries.[47] The changes made led to criticism of both India's patent laws and Cipla.[48] India reinstated patents on drugs in 2005.[46]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ "Annual Report 2023-24" (PDF). Archived (PDF) from the original on 5 October 2024. Retrieved 24 May 2025.
  2. ↑ "Q4 & FY25 results" (PDF). Cipla. Archived (PDF) from the original on 14 May 2025. Retrieved 24 May 2025.
  3. ↑ "Audited Financial Results (Standalone and Consolidated) for year ended 31st March 2025" (PDF). Cipla. Retrieved 24 May 2025.
  4. ↑ "Cipla betting big on digitisation and emerging segments". The Economic Times. Retrieved 6 December 2022.
  5. ↑ "Cipla betting big on digitisation and emerging segments". Financial Express. Retrieved 6 December 2022.
  6. ↑ 6.0 6.1 "About us - History". Cipla Limited. Archived from the original on 27 October 2015. Retrieved 3 November 2014.
  7. ↑ 7.0 7.1 "Company History - Cipla Ltd". Economic Times. Archived from the original on 15 November 2013. Retrieved 3 November 2013.
  8. ↑ 8.0 8.1 Eban, Katherine (2019). Bottle of Lies. HarperCollins. pp. 69–73. ISBN 9780062338785.
  9. ↑ 9.0 9.1 Dec 22, PTI (22 December 2022). "Indian pharma sector set for 'volume to value leadership' journey in 2023". The Economic Times. ISSN 0013-0389. Archived from the original on 5 August 2023. Retrieved 5 August 2023.{{cite news}}: CS1 maint: numeric names: authors list (link)
  10. ↑ "Introducing IPA- Indian Pharmaceutical Alliance". IPA, Indian Pharmaceutical Alliance. Archived from the original on 9 April 2024. Retrieved 5 August 2023.
  11. ↑ 11.0 11.1 "Epic saga of Cipla: How a swadeshi Robin Hood took on Big Pharma of the West". The Economic Times. 5 August 2023. ISSN 0013-0389. Retrieved 5 August 2023.
  12. ↑ 12.0 12.1 Jawani, Lohit (16 July 2013). "Cipla completes acquisition of South Africa's Cipla Medpro". VC Circle. Archived from the original on 15 March 2016. Retrieved 8 September 2016.
  13. ↑ "Delists from JSE". Business Day Live. 2013. Archived from the original on 1 August 2013. Retrieved 13 July 2013.
  14. ↑ "Enaleni Pharmaceuticals Limited Prospectus 2005". Morningstar. Archived from the original on 19 September 2016. Retrieved 8 September 2016.
  15. ↑ Avafia, Tenu; Berger, Jonathan; Hartzenberg, Trudi (2006). "The ability of select sub-Saharan African countries to utilise TRIPs Flexibilities and Competition Law to ensure a sustainable supply of essential medicines: A study of producing and importing countries" (PDF). WHO. Archived from the original (PDF) on 23 January 2014.
  16. ↑ Kahn, Tamar (10 September 2008). "South Africa: Enaleni Takes Name of Its Unit Cipla-Medpro". All Africa.
  17. ↑ Priyan, Vishnu (5 September 2023). "Cipla to bolster OTC portfolio with acquisition of Actor Pharma". Pharmaceutical Technology. Archived from the original on 5 September 2023. Retrieved 5 September 2023.
  18. ↑ JARVIS, LISA (4 September 2006). "Mylan Will Buy Most of Matrix". Chemical & Engineering News Archive. 84 (36): 8. doi:10.1021/cen-v084n036.p008. ISSN 0009-2347.
  19. ↑ "Cipla's History". Cipla South Africa. n.d. Archived from the original on 26 May 2022. Retrieved 16 May 2022.
  20. ↑ "Cipla to acquire Ivia Beaute's cosmetics, personal care biz for Rs 130 cr". Business Standard India. Press Trust of India. 16 April 2024. Archived from the original on 21 April 2024. Retrieved 21 April 2024.
  21. ↑ 21.0 21.1 "cipla ltd (CIPLA:Natl India)". Business Week. Retrieved 7 November 2013.{{cite web}}: CS1 maint: deprecated archival service (link)
  22. ↑ "Annual Report FY 2022-23" (PDF). Cipla.com. Cipla. 15 July 2014. Archived (PDF) from the original on 11 October 2023. Retrieved 11 October 2023.
  23. ↑ "AIDS Healthcare Foundation Campaign Challenges Cipla Over Drug Pricing in India" (Press release). PR Newswire. 8 August 2007. Archived from the original on 29 August 2014. Retrieved 4 November 2013.
  24. ↑ "India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug". Reuters. 21 June 2020. Archived from the original on 5 August 2020. Retrieved 7 August 2020.
  25. ↑ "Coronavirus drug: Cipla launches Cipremi's, claims it is the cheapest Remdesivir". The Financial Express. 9 July 2020. Archived from the original on 15 August 2020. Retrieved 7 August 2020.
  26. ↑ "Coronavirus drug: Cipla ramps up production of antiviral remdesivir amid demand spurt". businesstoday.in.
  27. ↑ "Corporate Information: At a Glance". Cipla. Archived from the original on 12 September 2016. Retrieved 6 July 2019.
  28. ↑ "Cipla in the pink of health". Business Standard. 25 September 2013. Archived from the original on 2 October 2014. Retrieved 5 November 2013.
  29. ↑ 29.0 29.1 29.2 "Annual Report 2013-14" (PDF). Cipla. 22 August 2014. Archived from the original (PDF) on 22 January 2015. Retrieved 17 September 2014.
  30. ↑ "Cipla Limited". BSEindia.com. Archived from the original on 4 November 2013. Retrieved 2 November 2013.
  31. ↑ "Scripwise Weightages in S&P BSE SENSEX". BSE India. Archived from the original on 1 December 2015. Retrieved 2 November 2013.
  32. ↑ "NTPC Limited". NSE India. Archived from the original on 4 March 2016. Retrieved 2 November 2013.
  33. ↑ "Download List of CNX Nifty stocks (.csv)". NSE India. Archived from the original on 13 October 2013. Retrieved 2 November 2013.
  34. ↑ "StockEdge". web.stockedge.com. Archived from the original on 25 January 2023. Retrieved 25 January 2023.
  35. ↑ "Latest CIPLA Shareholding Pattern". Equitymaster. Archived from the original on 25 January 2023. Retrieved 25 January 2023.
  36. ↑ "Company Profile - Cipla Limited". IndiaInfoline.com. Archived from the original on 5 November 2013. Retrieved 3 November 2013.
  37. ↑ "Pharmaceutical sector award". Dun & Bradstreet. 10 September 2006. Retrieved 3 November 2013.{{cite web}}: CS1 maint: deprecated archival service (link)
  38. ↑ "Asian Paints, Cipla in Forbes list". Economic Times. 17 November 2005. Archived from the original on 4 November 2013. Retrieved 3 November 2013.
  39. ↑ "DBT, Cipla get Thomson Reuters India innovation awards". Archived from the original on 22 July 2013. Retrieved 24 November 2012.
  40. ↑ "Lupin, Sun Pharma and Cipla amongst tops most reputed pharma brand list". The Economic Times. timesofindia.com. 17 August 2016. Retrieved 6 July 2019.
  41. ↑ "Home". bluebytes.info. Archived from the original on 1 August 2018. Retrieved 7 August 2022.
  42. ↑ "Home". trustadvisory.info. Archived from the original on 2 November 2017. Retrieved 7 August 2022.
  43. ↑ "Cipla rises on morning-after pill". Hindustan Times. 5 October 2007. Archived from the original on 5 February 2015. Retrieved 3 November 2013.
  44. ↑ "Cipla Launches i-pill". Financial Express. Archived from the original on 4 November 2013. Retrieved 3 November 2013.
  45. ↑ "'i-pill' by Cipla draws criticism from experts". Financial Express. 27 October 2007. Archived from the original on 4 November 2013. Retrieved 3 November 2013.
  46. ↑ 46.0 46.1 "The Treasure of Mumbai". Wired Magazine. December 2006. Retrieved 4 November 2013.
  47. ↑ "Heart-warming story of the Hamieds, who set up CIPLA and have been saving lives". National Herald. April 2020. Retrieved 12 April 2020.
  48. ↑ "Indian Generic Drug Maker Targets Sad Americans". biohealthinvestor.com. 3 January 2007. Archived from the original on 22 August 2012. Retrieved 4 November 2013.

External links[edit | edit source]

Template:CNX Nifty companies

Retrieved from "https://en.bharatpedia.org/w/index.php?title=Cipla&oldid=471517"
Discover more